Rhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC boosted its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 956.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,254 shares of the company’s stock after acquiring an additional 12,000 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Rhythm Pharmaceuticals were worth $1,339,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of Rhythm Pharmaceuticals in the 2nd quarter worth approximately $13,105,000. Intech Investment Management LLC lifted its stake in Rhythm Pharmaceuticals by 20.7% during the first quarter. Intech Investment Management LLC now owns 33,893 shares of the company’s stock valued at $1,795,000 after purchasing an additional 5,801 shares during the last quarter. Alkeon Capital Management LLC boosted its holdings in Rhythm Pharmaceuticals by 24.5% during the second quarter. Alkeon Capital Management LLC now owns 1,017,700 shares of the company’s stock worth $64,308,000 after buying an additional 200,000 shares in the last quarter. Harbor Capital Advisors Inc. grew its position in Rhythm Pharmaceuticals by 12.0% in the second quarter. Harbor Capital Advisors Inc. now owns 86,546 shares of the company’s stock worth $5,469,000 after buying an additional 9,249 shares during the last quarter. Finally, Toth Financial Advisory Corp bought a new position in shares of Rhythm Pharmaceuticals in the second quarter valued at $632,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on RYTM shares. Oppenheimer lowered Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 5th. Citizens Jmp lifted their price target on Rhythm Pharmaceuticals from $141.00 to $167.00 and gave the stock a “market outperform” rating in a research note on Friday, December 12th. JMP Securities boosted their price objective on Rhythm Pharmaceuticals from $135.00 to $142.00 and gave the stock a “market outperform” rating in a report on Thursday, September 25th. Cowen reaffirmed a “buy” rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, December 11th. Finally, Wall Street Zen downgraded shares of Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $130.00.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other news, insider Pamela J. Cramer sold 3,350 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $111.00, for a total transaction of $371,850.00. Following the transaction, the insider directly owned 20,814 shares in the company, valued at $2,310,354. The trade was a 13.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Joseph Shulman sold 9,748 shares of the company’s stock in a transaction on Thursday, October 30th. The stock was sold at an average price of $115.24, for a total transaction of $1,123,359.52. Following the completion of the transaction, the insider directly owned 8,509 shares in the company, valued at $980,577.16. This trade represents a 53.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 15,913 shares of company stock worth $1,818,963. 6.10% of the stock is currently owned by corporate insiders.

Rhythm Pharmaceuticals Price Performance

NASDAQ:RYTM opened at $113.34 on Thursday. The stock has a market cap of $7.56 billion, a PE ratio of -36.56 and a beta of 2.00. Rhythm Pharmaceuticals, Inc. has a fifty-two week low of $45.90 and a fifty-two week high of $122.20. The stock’s 50-day moving average is $105.70 and its two-hundred day moving average is $99.45.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.10). The company had revenue of $51.30 million for the quarter, compared to analyst estimates of $50.71 million. Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%. On average, equities research analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.